Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Relacorilant/nab-paclitaxel significantly improved PFS and OS vs nab-paclitaxel alone in platinum-resistant ovarian cancer.

Alicia Morgans, MD, MPH, discusses the phase 3 ARASTEP trial evaluating darolutamide in patients at high risk of biochemical recurrence of prostate cancer.

Vincent Picozzi, MD, discusses findings from the phase 3 trial PANOVA-3 of TTFields with gemcitabine and nab-paclitaxel in locally advanced pancreatic cancer.

Darolutamide is now an FDA-approved treatment option alone or in combination with docetaxel for metastatic ...

If approved, ziftomenib could be the first FDA-approved Menin inhibitor for relapsed/refractory acute myeloid leukemia with ...

Panelists discuss how new treatments like rusfertide (a hepcidin mimetic) offer promising options for polycythemia vera patients, demonstrating benefits in reducing phlebotomy requirements while ...

The primary end point, major pathologic response (MPR), was reviewed per consensus criteria and centrally confirmed: In the monotherapy arm, the MPR rate was 33.3%, with all responses being pathologic ...

Linda Duska, MD, FASCO, MPH, discusses the importance of the KEYNOTE-A18 study reinforcing the new standard of care of pembrolizumab plus concurrent chemoradiotherapy in locally advanced cervical ...

In the VERIFY study, rusfertide significantly improved clinical responses vs placebo in polycythemia vera, offering a ...

EBC-129 demonstrates early activity and manageable safety in patients with heavily pretreated pancreatic cancer, supporting ...

Hecht, MD, discusses the phase 3 OrigAMI-3 trial for patients with recurrent, unresectable, or metastatic RAS/BRAF wild-type colorectal cancer.